ILC Therapeutics raises £3.5m to advance lead interferon drug candidate
UK-based biotech company ILC Therapeutics has announced the successful completion of a £3.5m pre-IPO funding round.
We use necessary cookies to make our site work. We'd also like to set analytical cookies to help us improve our service, but we'd like your permission first. Please choose which cookies you're happy for us to set.